Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report

BACKGROUND: The overexpression of human epidermal growth factor receptor 2 (HER2) is strongly correlated with an elevated risk of developing distant metastases, particularly brain metastases, in breast cancer (BC) cases. RC48 (also known as Disitamab vedotin), represents a promising antibody-drug co...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Fei, Liu, Qian, Lu, Rongrong, Li, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498115/
https://www.ncbi.nlm.nih.gov/pubmed/37711199
http://dx.doi.org/10.3389/fonc.2023.1245701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498115/
https://www.ncbi.nlm.nih.gov/pubmed/37711199
http://dx.doi.org/10.3389/fonc.2023.1245701

Ejemplares similares